A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents

  title={A Review of Cannabis and Interactions With Anticoagulant and Antiplatelet Agents},
  author={J. Greger and Vernice Bates and Laszlo L. Mechtler and Francis M. Gengo},
  journal={The Journal of Clinical Pharmacology},
Legalization of medical cannabis has occurred in 33 states and the District of Columbia, and recreational use has increased exponentially since 2013. As a result, it is important to understand how cannabis interacts with other drugs and has potential risks for patients on concomitant medications. Components of medical cannabis can inhibit or compete for several cytochrome P450 (CYP) hepatic isoenzymes, UDP‐glucuronosyltransferases, and P‐glycoprotein. These enzymes and transporters are involved… 

Cannabidiol drug interaction considerations for prescribers and pharmacists

An overview of evidence-based pharmacokinetic predictions and general guidance about the dose range at which clinically relevant cannabidiol drug interactions are likely is provided.

Clinical Relevance of Drug Interactions with Cannabis: A Systematic Review

Evidence is provided for both the low probability of the occurrence of clinically relevant drug interactions and the lack of evidence regarding cannabis–drug interactions.

Cannabis Drug Interactions

This chapter will provide an overview of the routes of administration as well as highlight potential drug interactions that cannabis products may have with particular classes of pharmaceuticals.

Pharmacokinetic considerations about antiseizure medications in the elderly

Overall, a reduction in loading and maintenance doses of almost all ASMs should be considered to avoid adverse events (AEs) as well as a slow titration, following the rule ‘start low and go slow’.

ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids

Specific clinical recommendations for perioperative management of cannabis and cannabinoids were successfully created and surgical patients using cannabinoids are at potential increased risk for negative perioperatively outcomes.

A critical narrative review of medical cannabis in pediatrics beyond epilepsy, part I: background

The current understanding of the medical use of cannabis is limited by lack of optimal dosing, long-term efficacy, safety, and drug interaction data in the pediatric population, prompting the need for additional research.

In vitro inhibitory effect of obtusofolin on the activity of CYP3A4, 2C9, and 2E1

The in vitro inhibitory effect of obtusofolin is found to significantly inhibited the activity of CYP3A4, 2C9, and 2E1, implying the potential drug-drug interaction between obtUSofolin and corresponding substrates, which needs further in vivo validations.

Translational hurdles with cannabis medicines

The utility, limitations and impact of RWE in the translation of cannabis medicines research into clinical practice using the established literature are explored.



Interaction between warfarin and cannabis

A case report of a 27-year-old man treated with warfarin due to mechanical heart valve replacement who presented with elevated international normalized ratio (INR) value ( INR = 4.6) following recreational cannabis use is described.

The pharmacokinetics and the pharmacodynamics of cannabinoids.

The limited availability of applicable pharmacokinetic and pharmacodynamic information highlights the need to initiate prescribing cannabis medicines using a 'start low and go slow' approach, carefully observing the patient for desired and adverse effects.

Medicinal Cannabis—Potential Drug Interactions

In general, cannabinoids are usually well tolerated, but bidirectional effects may be expected with concomitant administered agents via affected membrane transporters and metabolizing enzymes, especially for the elderly and people with chronic diseases or kidney and liver conditions.

Probable Interaction Between Warfarin and Inhaled and Oral Administration of Cannabis

There are no previous reports of interactions between edible cannabis and warfarin, with very few case reports describing the interaction with other forms of cannabis, but close monitoring of INR in patients with concomitant cannabis is recommended for proper warfar in management.

Evaluating the Effect of Six Proton Pump Inhibitors on the Antiplatelet Effects of Clopidogrel.

The Potential for Pharmacokinetic Interactions Between Cannabis Products and Conventional Medications.

This review aims to identify drug-metabolizing enzymes and drug transporters that are affected by concurrent cannabis use and, conversely, those co-prescribed medications that may alter the exposure to one or more cannabinoids.

New Direct Oral Anticoagulants (DOAC) and Their Use Today

The properties of oral administration, simple dosing without monitoring, a short half-life allowing for the possibility of uncomplicated switching or bridging, and proven safety overwhelm the disadvantages, making them an attractive option for short- or long-term anticoagulation.

Novel antiplatelet agents in acute coronary syndrome

The novel oral P2Y purinoceptor 12 (P2Y12)-receptor inhibitors prasugrel and ticagrelor were approved by the FDA for clinical use in 2009 and 2011 and have a faster-acting, more-potent, and more-predictable antiplatelet effect than clopidogrel.

Cannabinoids and Cytochrome P450 Interactions.

The interplay of central cannabinoid receptors with numerous nervous systems, resulting in a hormone-mediated signal towards nuclear receptors in hepatocytes is hypothesized.